文献速递白血病

青少年和年轻成人患者(16至30岁)与较年轻患者在高危B淋巴细胞白血病治疗后的结局比较:儿童肿瘤学组AALL0232研究报道

Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232.
PubMed 文献 · Leukemia · 2021-11-01

AALL0232是一项儿童肿瘤学组针对新诊断高危B急性淋巴细胞白血病(1-30岁)的3期随机试验,2004至2011年入组3154例,3040例可评估诱导。青少年和年轻成人(AYA)患者占20%(16-21岁551例,22-30岁46例),其5年无事件生存率和总生存率分别为65.4±2.2%和77.4±2.0%,低于较年轻患者的78.1±0.9%和87.3±0.7%(p<0.0001)。

要点

  • AYA患者5年无事件生存率65.4±2.2%,较年轻患者78.1±0.9%(p<0.0001)。
  • AYA患者5年累积复发率18.5±1.7%,较年轻患者13.5±0.7%(p=0.006),主要因骨髓复发增加。
  • AYA患者诱导失败率和诱导后缓解期死亡率均显著高于较年轻患者。

核心结论

  • AALL0232入组了迄今最大数量的AYA B-ALL患者,显示AYA患者生存显著劣于较年轻患者,且治疗相关毒性发生率更高。
  • 尽管治疗强化改善了较年轻患者的结局,但并未给较年长患者带来同等程度的改善。

研究设计与样本

  • AALL0232是一项儿童肿瘤学组的3期随机试验,针对新诊断高危B急性淋巴细胞白血病(1-30岁)。
  • 2004年至2011年间入组3154例,其中3040例符合条件并可评估诱导。
  • AYA患者占20%(16-21岁551例;22-30岁46例)。

主要发现

  • AYA患者5年无事件生存率为65.4±2.2%,较年轻患者为78.1±0.9%(p<0.0001)。
  • AYA患者5年总生存率为77.4±2.0%,较年轻患者为87.3±0.7%(p<0.0001)。
  • AYA患者5年累积复发率为18.5±1.7%,较年轻患者为13.5±0.7%(p=0.006),主要因骨髓复发增加(14.0±1.5% vs 9.1±0.6%;p<0.0001)。
  • AYA患者诱导失败率为7.2±1.1%,较年轻患者为3.5±0.4%(p<0.001);诱导后缓解期死亡率AYA为5.7±1.0%,较年轻患者为2.4±0.3%(p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adolescent and young adult (AYA) patients 16-30 years old with high-risk acute lymphoblastic leukemia (HR-ALL) have inferior outcomes compared to younger HR-ALL patients. AALL0232 was a Phase 3 randomized Children's Oncology Group trial for newly diagnosed HR B-ALL (1-30 years). Between 2004 and 2011, 3154 patients enrolled with 3040 eligible and evaluable for induction. AYA patients comprised 20% of patients (16-21 years, n = 551; 22-30 years, n = 46). 5-year event-free survival and overall survival was 65.4 ± 2.2% and 77.4 ± 2.0% for AYA patients compared to 78.1 ± 0.9% and 87.3 ± 0.7% for younger patients (p < 0.0001). Five-year cumulative incidence of relapse was 18.5 ± 1.7% for AYA patients and 13.5 ± 0.7% for younger patients (p = 0.006), largely due to increased marrow relapses (14.0 ± 1.5% versus 9.1 ± 0.6%; p < 0.0001). Additionally, induction failure rate was higher in AYA (7.2 ± 1.1% versus 3.5 ± 0.4%; p < 0.001) and post-induction remission deaths were significantly higher in AYA (5.7 ± 1.0% versus 2.4 ± 0.3%; p < 0.0001). AALL0232 enrolled the largest number of AYA B-ALL patients to date, demonstrating significantly inferior survival and greater rates of treatment-related toxicities compared to younger patients. Although treatment intensification has improved outcomes in younger patients, they have not been associated with the same degree of improvement for older patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Burke MJ, Devidas M, Chen Z, et al. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. Leukemia. 2021. PMID: 34725453. doi:10.1038/s41375-021-01460-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。